Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.130
-0.190 (-5.72%)
At close: Oct 14, 2026, 4:00 PM EDT
3.129
-0.001 (-0.02%)
After-hours: Oct 14, 2026, 7:57 PM EDT
Prime Medicine Employees
Prime Medicine had 146 employees as of December 31, 2025. The number of employees decreased by 68 or -31.78% compared to the previous year. That makes Prime Medicine the 28,996th largest employer in the world and 3,705th in the United States.
Employees
146
Change (1Y)
-68
Growth (1Y)
-31.78%
Revenue / Employee
$27,897
Profits / Employee
-$1,286,932
Market Cap
556.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 146 | -68 | -31.78% |
| Dec 31, 2024 | 214 | -20 | -8.55% |
| Dec 31, 2023 | 234 | 59 | 33.71% |
| Dec 31, 2022 | 175 | 74 | 73.27% |
| Sep 30, 2022 | 150 | 86 | 134.38% |
| Jun 30, 2022 | 137 | 73 | 114.06% |
| Mar 31, 2022 | 101 | - | - |
| Sep 30, 2021 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Pharming Group | 407 |
| Wave Life Sciences | 317 |
| Olema Pharmaceuticals | 150 |
| Aura Biosciences | 113 |
| OmniAb | 89 |
| Crescent Biopharma | 69 |
| Zevra Therapeutics | 61 |
PRME News
- 9 days ago - Prime Medicine doses first patient in PM577a trial - TheFly
- 9 days ago - Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease - GlobeNewsWire
- 10 days ago - Prime Medicine Slides: Corporate presentation - Filings
- 20 days ago - Prime Medicine announces FDA clearance of IND application for PM647 - TheFly
- 20 days ago - Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 4 weeks ago - Prime Medicine Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - Prime Medicine Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire